Modified Taiwan Atrial Fibrillation Score for the Prediction of Incident Atrial Fibrillation.

Asian population incident atrial fibrillation modified Taiwan AF score national cohort prediction

Journal

Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388

Informations de publication

Date de publication:
2021
Historique:
received: 30 10 2021
accepted: 27 12 2021
entrez: 14 2 2022
pubmed: 15 2 2022
medline: 15 2 2022
Statut: epublish

Résumé

We have proposed the Taiwan AF score consisting of age, male sex, hypertension, heart failure, coronary artery disease, end-stage renal disease, and alcoholism to predict incident atrial fibrillation (AF) in Asian population. We hypothesized that the modified Taiwan AF score (mTaiwan AF score) excluding alcoholism remained useful for predicting new onset AF. A total of 7,220,654 subjects aged ≥ 40 years without a past history of cardiac arrhythmia were identified from a national cohort, and 438,930 incident AF occurred during a 16-year follow-up with an incidence of 0.42 per 100 person-years. The mTaiwan AF score ranging between -2 and 14 and its predictive accuracy of incident AF was analyzed. The areas under the receiver operating characteristic curve (AUCs) of the mTaiwan AF scores in predicting AF are 0.861 for 1-year follow-up, 0.829 for 5-year follow-up, 0.795 for 10-year follow-up, and 0.751 for 16-year follow-up. The risk of incident AF increased from 0.05%/year for patients with a score of -2 to 6.98%/year for those having a score of 14. Patients were classified into three groups based on the tertile values of the mTaiwan AF scores-group 1 (score -2-3), group 2 (score 4-9) and group 3 (score 10-14). The annual risks of incident AF were 0.20, 1.33, and 3.36% for group 1, 2, and 3, respectively. Compared to patients in group 1, the hazard ratios of incident AF were 5.79 [95% confidence interval (CI) 3.75-7.75] for group 2 and 8.93 (95% CI 6.47-10.80) for group 3. We demonstrated that the mTaiwan AF score based on age and clinical comorbidities could be used to predict incident AF in Asian population.

Sections du résumé

BACKGROUND BACKGROUND
We have proposed the Taiwan AF score consisting of age, male sex, hypertension, heart failure, coronary artery disease, end-stage renal disease, and alcoholism to predict incident atrial fibrillation (AF) in Asian population. We hypothesized that the modified Taiwan AF score (mTaiwan AF score) excluding alcoholism remained useful for predicting new onset AF.
METHODS METHODS
A total of 7,220,654 subjects aged ≥ 40 years without a past history of cardiac arrhythmia were identified from a national cohort, and 438,930 incident AF occurred during a 16-year follow-up with an incidence of 0.42 per 100 person-years. The mTaiwan AF score ranging between -2 and 14 and its predictive accuracy of incident AF was analyzed.
RESULTS RESULTS
The areas under the receiver operating characteristic curve (AUCs) of the mTaiwan AF scores in predicting AF are 0.861 for 1-year follow-up, 0.829 for 5-year follow-up, 0.795 for 10-year follow-up, and 0.751 for 16-year follow-up. The risk of incident AF increased from 0.05%/year for patients with a score of -2 to 6.98%/year for those having a score of 14. Patients were classified into three groups based on the tertile values of the mTaiwan AF scores-group 1 (score -2-3), group 2 (score 4-9) and group 3 (score 10-14). The annual risks of incident AF were 0.20, 1.33, and 3.36% for group 1, 2, and 3, respectively. Compared to patients in group 1, the hazard ratios of incident AF were 5.79 [95% confidence interval (CI) 3.75-7.75] for group 2 and 8.93 (95% CI 6.47-10.80) for group 3.
CONCLUSIONS CONCLUSIONS
We demonstrated that the mTaiwan AF score based on age and clinical comorbidities could be used to predict incident AF in Asian population.

Identifiants

pubmed: 35155613
doi: 10.3389/fcvm.2021.805399
pmc: PMC8831699
doi:

Types de publication

Journal Article

Langues

eng

Pagination

805399

Informations de copyright

Copyright © 2022 Liao, Lim, Chen, Tuan, Chen and Chao.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Formos Med Assoc. 2005 Mar;104(3):157-63
pubmed: 15818428
Circulation. 2018 Jul 3;138(1):37-47
pubmed: 29490992
Eur J Clin Invest. 2021 Jun;51(6):e13488
pubmed: 33420738
Chest. 2018 Feb;153(2):453-466
pubmed: 29017957
Eur J Cardiovasc Prev Rehabil. 2010 Dec;17(6):706-12
pubmed: 21461366
Heart Rhythm. 2013 Jul;10(7):1082-8
pubmed: 23501173
Circulation. 2004 Aug 31;110(9):1042-6
pubmed: 15313941
Stat Med. 2004 May 30;23(10):1631-60
pubmed: 15122742
Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):236-42
pubmed: 21351304
Am Heart J. 1978 May;95(5):555-62
pubmed: 636996
Eur Heart J Qual Care Clin Outcomes. 2021 Jul 24;:
pubmed: 34302335
Nat Rev Cardiol. 2014 Nov;11(11):639-54
pubmed: 25113750
Heart Rhythm. 2021 Jun;18(6):871-877
pubmed: 33640447
J Am Coll Cardiol. 2011 Jan 25;57(4):427-36
pubmed: 21251583
Eur Heart J. 2021 Mar 21;42(12):1170-1177
pubmed: 33438022
J Am Heart Assoc. 2021 Sep 7;10(17):e020194
pubmed: 34459227
Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):632-9
pubmed: 22787011
Heart. 2007 May;93(5):542-3
pubmed: 17435064
Circulation. 2006 Aug 15;114(7):e257-354
pubmed: 16908781
Mayo Clin Proc. 2021 Jan;96(1):52-65
pubmed: 33413835
Eur Heart J. 2019 May 14;40(19):1504-1514
pubmed: 30605505
Am Heart J. 2018 Aug;202:20-26
pubmed: 29802976
Int J Cardiol. 2017 Nov 1;246:46-52
pubmed: 28867013
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
J Am Heart Assoc. 2013 Mar 18;2(2):e000102
pubmed: 23537808
Clin Res Cardiol. 2022 Jan;111(1):23-33
pubmed: 33704551
Circulation. 2014 Feb 25;129(8):837-47
pubmed: 24345399
Am J Cardiol. 2011 Jan;107(1):85-91
pubmed: 21146692
Lancet. 2009 Feb 28;373(9665):739-45
pubmed: 19249635
Atherosclerosis. 2014 Jan;232(1):224-30
pubmed: 24401243
J Am Coll Cardiol. 2014 Jul 22;64(3):281-9
pubmed: 25034065
J Am Coll Cardiol. 2016 Dec 13;68(23):2567-2576
pubmed: 27931615
Circ J. 2014;78(4):955-61
pubmed: 24553265
Kidney Int. 2015 Jun;87(6):1209-15
pubmed: 25587708
PLoS One. 2013 May 21;8(5):e63479
pubmed: 23704912

Auteurs

Jo-Nan Liao (JN)

Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Su-Shen Lim (SS)

Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Tzeng-Ji Chen (TJ)

Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Ta-Chuan Tuan (TC)

Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Shih-Ann Chen (SA)

Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan.

Tze-Fan Chao (TF)

Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Classifications MeSH